|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Fenofibrate]] |
| {{Fenofibrate}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| ===Primary Hypercholesterolemia and Mixed Dyslipidemia===
| |
| | |
| Antara is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary [[hyperlipidemia]] or mixed [[dyslipidemia]].
| |
| | |
| ===Severe Hypertriglyceridemia===
| |
| | |
| Antara is also indicated as adjunctive therapy to diet for treatment of adult patients with [[hypertriglyceridemia]]. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention.
| |
| | |
| Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing [[pancreatitis]]. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.
| |
| | |
| ===Important Limitations of Use===
| |
| | |
| Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 [[diabetes mellitus ]][see Warnings and Precautions (5.1)].<ref>{{Cite web | last = | first = | title = ANTARA (FENOFIBRATE) CAPSULE [LUPIN PHARMA] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12ebf783-64df-4ffa-9e84-f8fdf4d245d4 | publisher = | date = | accessdate = 12 February 2014 }}</ref> | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| {{Lipid modifying agents}}
| |
| {{Antigout preparations}}
| |
| | |
| [[Category:Fibrates]]
| |
| [[Category:Prodrugs]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Benzophenones]]
| |
| [[Category:Phenol ethers]]
| |
| [[Category:Carboxylate esters]]
| |